Adjuvant Bidirectional Chemotherapy Using an Intraperitoneal Port
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been established as treatment options for patients with peritoneal metastases or peritoneal mesothelioma. However, this novel treatment strategy remains associated with a large percentage of local-regional treatm...
Saved in:
| Main Authors: | Paul H. Sugarbaker, Lana Bijelic |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/752643 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of hyperthermic intraperitoneal chemotherapy in combination with an intraperitoneal port system in the treatment of patients with advanced ovarian cancer
by: V. V. Saevets, et al.
Published: (2022-01-01) -
Association between time to adjuvant chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
by: Sergei Iugai, et al.
Published: (2025-04-01) -
The Controversy of Intraperitoneal Hyperthermic Chemotherapy for Ovarian Cancer
by: Lucian ALECU, et al.
Published: (2020-12-01) -
Cytoreductive Surgery Plus Hyperthermic Perioperative Chemotherapy for Selected Patients with Peritoneal Metastases from Colorectal Cancer: A New Standard of Care or an Experimental Approach?
by: Paul H. Sugarbaker
Published: (2012-01-01) -
Study on Performance of Nebulizer for Pressurized Intraperitoneal Aerosol Chemotherapy
by: Lanfeng ZHANG, et al.
Published: (2025-05-01)